ConductScience.org, home

Paper20049949

Direct comparison of two different mesalamine formulations for the maintenance of remission in patients with ulcerative colitis: a double-blind, randomized study.

Ito H and 7 others. Inflamm Bowel Dis, 2010. Cited by 20 papers, by iCite.

Cite this record

ConductScience Library. Direct comparison of two different mesalamine formulations for the maintenance of remission in patients with ulcerative colitis: a double-blind, randomized study. Papers, record 20049949. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/20049949

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Direct comparison of two different mesalamine formulations for the maintenance of remission in patients with ulcerative colitis: a double-blind, randomized study.
PubMed
Journal
Inflamm Bowel Dis
PubMed
Year
2010
PubMed
Publication types
Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
20
iCite
Relative citation ratio, by iCite
0.73
iCite
Revised in PubMed
2021-10-20
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Ito HHiroaki
2Iida MMitsuo
3Matsumoto TTakayuki
4Suzuki YYasuo
5Aida YYoshiyuki
6Yoshida TToyomitsu
7Takano YYuichi
8Hibi TToshifumi

Source PubMed

Download CSV of authors

Topics21

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Anti-Inflammatory Agents, Non-SteroidalMajor topic
Colitis, UlcerativeMajor topic
MesalamineMajor topic
Pharmaceutical PreparationsMajor topic
Adolescent
Adult
Aged
Chemistry, Pharmaceutical
Double-Blind Method
Female
Follow-Up Studies
Humans
Hydrogen-Ion Concentration
Male
Middle Aged
Remission Induction
Severity of Illness Index
Survival Rate
Time Factors
Treatment Outcome
Young Adult

Source PubMed

Download CSV of topics

References16

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
115929768Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies.Am J Gastroenterol2005https://conductscience.org/library/papers/15929768PubMed
28533995An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. The Mesalamine Study Group.Ann Intern Med1996https://conductscience.org/library/papers/8533995PubMed
335697655-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis.Gastroenterology1987https://conductscience.org/library/papers/3569765PubMed
415233681Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee.Am J Gastroenterol2004https://conductscience.org/library/papers/15233681PubMed
53678967Effect of polymer coating on faecal recovery of ingested 5-amino salicylic acid in patients with ulcerative colitis.Gut1987https://conductscience.org/library/papers/3678967PubMed
614075156VARIATION BETWEEN OBSERVERS IN DESCRIBING MUCOSAL APPEARANCES IN PROCTOCOLITIS.Br Med J1964https://conductscience.org/library/papers/14075156PubMed
726193460A critical review of endoscopic indices in ulcerative colitis: inter-observer variation of the endoscopic index.Clin J Gastroenterol2008https://conductscience.org/library/papers/26193460PubMed
811151878Intravenous azathioprine in severe ulcerative colitis: a pilot study.Am J Gastroenterol2000https://conductscience.org/library/papers/11151878PubMed
97851193Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group.Dig Dis Sci1995https://conductscience.org/library/papers/7851193PubMed
102684592Mesalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in chronic inflammatory bowel disease.Drugs1989https://conductscience.org/library/papers/2684592PubMed
1111515848
Measurement of colonic mucosal concentrations of 5-aminosalicylic acid is useful for estimating its therapeutic efficacy in distal ulcerative colitis: comparison of orally administered mesalamine and sulfasalazine.
Inflamm Bowel Dis2001https://conductscience.org/library/papers/11515848PubMed
123557190Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract.Gut1987https://conductscience.org/library/papers/3557190PubMed
1315306569Guidelines for the management of inflammatory bowel disease in adults.Gut2004https://conductscience.org/library/papers/15306569PubMed
143317057Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.N Engl J Med1987https://conductscience.org/library/papers/3317057PubMed
153207553Delayed-release mesalazine (5-aminosalicylic acid): coat dissolution and excretion in ileostomy subjects.Br J Clin Pharmacol1988https://conductscience.org/library/papers/3207553PubMed
16159942155-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study.Gut2005https://conductscience.org/library/papers/15994215PubMed

Download CSV of references

Cited by11

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 20 citations.

PMIDTitleJournalYearIn PapersSource
34631051pH-dependent vs. constant release of mesalazine in the treatment of ulcerative colitis: Do drug delivery concepts determine therapeutic efficacy? (Review).Biomed Rep2021https://conductscience.org/library/papers/34631051PubMed
32856298Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.Cochrane Database Syst Rev2020https://conductscience.org/library/papers/32856298PubMed
32778960Solving the questions regarding 5-aminosalitylate formulation in the treatment of ulcerative colitis.J Gastroenterol2020https://conductscience.org/library/papers/32778960PubMed
30576644AGA Clinical Practice Guidelines on the Management of Mild-to-Moderate Ulcerative Colitis.Gastroenterology2019https://conductscience.org/library/papers/30576644PubMed
30576642AGA Technical Review on the Management of Mild-to-Moderate Ulcerative Colitis.Gastroenterology2019https://conductscience.org/library/papers/30576642PubMed
30122356Comparative efficacy and tolerability of pharmacological agents for management of mild to moderate ulcerative colitis: a systematic review and network meta-analyses.Lancet Gastroenterol Hepatol2018https://conductscience.org/library/papers/30122356PubMed
28670233Comparison of efficacies of once-daily dose multimatrix mesalazine and multiple-dose mesalazine for the maintenance of remission in ulcerative colitis: a randomized, double-blind study.Intest Res2017https://conductscience.org/library/papers/28670233PubMed
28390410Real life results in using 5-ASA for maintaining mild to moderate UC patients in Japan, a multi-center study, OPTIMUM Study.BMC Gastroenterol2017https://conductscience.org/library/papers/28390410PubMed
283689092.4 g Mesalamine (Asacol 400 mg tablet) Once Daily is as Effective as Three Times Daily in Maintenance of Remission in Ulcerative Colitis: A Randomized, Noninferiority, Multi-center Trial.Inflamm Bowel Dis2017https://conductscience.org/library/papers/28368909PubMed
27158764Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.Cochrane Database Syst Rev2016https://conductscience.org/library/papers/27158764PubMed
22390554Mesalamine in the treatment and maintenance of remission of ulcerative colitis.Expert Rev Clin Pharmacol2012https://conductscience.org/library/papers/22390554PubMed

Download CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CRP1401PubTator's text mininghttps://conductscience.org/library/genes/1401NCBI Gene
FAS355PubTator's text mininghttps://conductscience.org/library/genes/355NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/20049949

GET https://conductscience.org/api/papers/v1/20049949/authors